Bayer oral anticoagulant Xarelto has gained positive common drug review (CDR) recommendation from the Canadian Agency for Drugs and Technologies in Health for the prevention of stroke and systemic embolism in atrial fibrillation (AF) ...
Tags: Bayer oral anticoagulant Xarelto, CDR Recommendation, Stroke Prevention
Quotient Clinical and Capsugel have partnered to accelerate early development and clinical evaluation of lipid-based formulations. The collaboration will focus on addressing the drug delivery challenges of poorly soluble molecules with ...
Tags: Quotient, Poorly Soluble Molecules, Capsugel
Capstone Therapeutics and LipimetiX have formed LipimetiX Development , a joint venture (JV), to develop drugs that are used to treat indications of lowering blood cholesterol levels. The JV will develop a family of Apo E mimetic peptides ...
Tags: Apolipoprotein E, lipoprotein metabolism, Capstone Therapeutics
KineMed has entered into a multi-year R&D collaboration GlaxoSmithKline (GSK) to develop kinetic biomarkers. The collaboration will apply KineMed's biomarker discovery platform in therapeutic areas of interest to GSK. KineMed president ...
Tags: kinetic biomarkers, GlaxoSmithKline, KineMed's technology
Unilife has developed two new technologies for delivering injectable therapies to targeted regions of the eye. The new technologies include Unilife Depot-Ject platform which allows clinicians to implant a solid or oil based drug into the ...
Biogen Idec (BIIB) and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement, pursuant to which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic ...
Tags: Steinert Disease, antisense drug
TI Pharma, Merck KGaA, Astellas Pharma and the Swiss Tropical and Public Health Institute (Swiss TPH) have entered into an international public-private partnership (PPP) to develop new pediatric formulation of praziquantel for the treatment ...
Tags: Pediatric Formulation, Swiss TPH, treatment of schistosomiasis
The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) has supported the clinical benefit of GlaxoSmithKline's raxibacumab to treat inhalational anthrax. In addition, the committee also favoured the ...
Tags: The Anti-Infective Drugs, raxibacumab anti-toxin development programme
Neurotech, a developer of active implantable devices, has received CE mark approval for its ADNS-300 to treat refractory epilepsy. The surgically implanted ADNS-300 system operates as a pacemaker to produce stimulation towards the brain ...
Tags: active implantable devices, Neurotech, refractory epilepsy
Researchers from the University of Almeria, Spain, have developed a new method which helps in finding the presence of most minute residues of drugs, which are actually given to livestock, in some infant foods. The researchers detected ...
Tags: Scientists, New Method, Veterinary Drugs, Infant Foods
The rlc packaging has completed the expansion of its PHARMACENTER in Rüdersdorf, Germany. The new production facility with doubled machine capacity is designed to meet the growing demand for pharmaceutical packaging, according to the ...
Tags: production facility, pharmaceutical packaging, new production line
CardioFocus has reported superior benefits of high-dose laser ablation using its cardiac ablation system when compared to low-dose treatment. Featuring an endoscope for intra-procedural visualization of the beating heart, the HeartLight ...
Tags: laser ablation, superior benefits, high-dose laser ablation
Basilea Pharmaceutica has commenced next pharmacokinetic Phase 1 study with antibiotic BAL30072 in healthy volunteers. The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to ...
India-based Exemed Pharmaceuticals, a manufacturer of active ingredients, is planning to buy UCB's production facility in Vapi, Gujarat, India. The deal, which is in line with UCB's strategy on bringing new drugs to patients and less on ...
XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m). The company has purchased single share at an amount of NIS1.405($0.36). The acquired shares represent all the ...
Tags: XTL Biopharmaceuticals, shares, drugs, multiple myeloma, schizophrenia